GlassScriptPhysician profile
Monica B Benulis
NPI 1912462243
$3,073.87
in general payments reported to CMS, 2019-2025
21 companies · $168 in 2025
The $168 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $457 · 2022: $853 · 2023: $900 · 2024: $697 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,744 · Education: $20.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,744.14 |
| Education | $20.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $752.79 | 2021-2025 | |
| Janssen Biotech, INC. | $382.88 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $355.06 | 2021-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $313.18 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Regeneron Healthcare Solutions, INC. | $197.57 | 2022-2024 | Dupixent |
| Genzyme Corporation | $154.83 | 2022-2024 | |
| Phathom Pharmaceuticals, INC. | $124.85 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $122.42 | 2021-2023 | Dificid |
| Celgene Corporation | $99.02 | 2021-2024 | Zeposia |
| Braintree Laboratories, INC. | $98.58 | 2022-2024 | Suflave, Sutab |
| Nestle Healthcare Nutrition INC. | $79.00 | 2022-2023 | |
| Ferring Pharmaceuticals INC. | $70.74 | 2021-2023 | Rebyota |
| Ardelyx, INC. | $59.19 | 2022-2023 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $58.49 | 2021-2023 | Ocaliva |
| Aimmune Therapeutics, INC. | $56.97 | 2024-2025 | Zenpep |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $50.87 | 2022-2023 | Amjevita |
| Daiichi Sankyo INC. | $28.76 | 2025 | Enhertu |
| Celltrion USA INC. | $20.55 | 2024 | Zymfentra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.29 | 2024 | Cyltezo |
| Sebela Pharmaceuticals INC. | $16.11 | 2023 | Sutab |
| Ironwood Pharmaceuticals, INC | $11.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Benulis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.